Clinical trials: CTLA-4
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor
CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor
This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen…
- Trial name
- NCT03182803
- Testing
- CTLA-4/PD-1 antibodies expressing mesoCAR-T
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Cell Therapy Research Institute
Graft Vs Host Disease, Graft-versus-host-disease
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies.
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
- Trial name
- NCT06008808
- Testing
- Ruxolitinib, Abatacept
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Washington University School of Medicine
Biliary Tract Cancers
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment…
- Trial name
- NCT06564623
- Testing
- mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Soft Tissue Sarcoma
Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma
This is a phase I, multicenter, open-label study starting with a dose exploration phase and followed by an expansion phase to evaluate the safety profile and the preliminary activity of the bispecific antibody anti PD-1/CTLA-4…
- Trial name
- MEDISARC-SBRT (NCT05821231)
- Testing
- SBRT + MEDI5752
- Where
- 5 sites in France
- Volunteers
- 14 people
- Sponsor
- Institut Claudius Regaud
Advanced/Metastatic Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of…
- Trial name
- NCT07857135
- Testing
- SYS6088, Regorafenib, Ivonescimab
- Volunteers
- 140 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Giant Cell Arteritis
Abatacept for the Treatment of Giant Cell Arteritis
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to…
- Trial name
- NCT04474847
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
NSCLC, Non-small Cell Lung Cancer
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Lung Cancer
- Trial name
- D4190C00006 (NCT02000947)
- Testing
- MEDI4736, Tremelimumab
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumor
CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor
This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen…
- Trial name
- NCT03182816
- Testing
- anti-CTLA-4/PD-1 expressing EGFR-CAR-T
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Cell Therapy Research Institute
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00058279
- Testing
- aldesleukin, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
This study is a single-arm study aimed at evaluating the efficacy and safety of Iparomlimab and Tuvonralimab Injection combined with apatinib and irinotecan hydrochloride in the treatment of advanced alpha-fetoprotein gastric…
- Conditions
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, Immunotherapy
- Trial name
- NCT07289997
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Hebei Medical University Fourth Hospital
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
The trial aimed to compare cadonilimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in high-risk locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- GEMSTONE (NCT05587374)
- Testing
- Cadonilimab, Gemcitabine, Cisplatin
- Where
- 18 sites in China
- Volunteers
- 490 people
- Sponsor
- Sun Yat-sen University
Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients…
- Conditions
- Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
- Trial name
- NCT04840589
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Advanced Hepatocellular Carcinoma
A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
To evaluate the efficacy and safety of cadonilimab combined with regorafenib in patients with HCC who progressed on systemic therapy.
- Trial name
- NCT05773105
- Testing
- Cadonilimab+regorafenib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC
Immunotherapy has made rapid progress in melanoma, Hodgkin's lymphoma, non-small cell lung cancer, and bladder cancer, etc. Preclinical data suggested that the use of anti-PD-1 antibody in combination with CTLA-4 receptor…
- Trial name
- SEQUENCE (NCT03527251)
- Testing
- Ipilimumab, SHR-1210
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
This is an open-label, three-cohort, phase Ib study to determine the safety, recommended phase 2 dose (RP2D), and efficacy of Stereotactic Body Radiation Therapy (SBRT) in combination with either (A) MEDI4736 alone, (B)…
- Trial name
- NCT02868632
- Testing
- MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 3 sites in United States
- Sponsor
- NYU Langone Health
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
This phase II trial studies the side effects and how well radiation therapy and durvalumab with or without tremelimumab work in treating participants with bladder cancer that cannot be removed by surgery, has spread to nearby…
- Conditions
- Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
- Trial name
- NCT03601455
- Testing
- Durvalumab, External Beam Radiation Therapy, Tremelimumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
This phase II trial studies the side effects and how well nivolumab with or with ipilimumab works in treating patients with liver cancer that can be removed by surgery.
- Trial name
- NCT03222076
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
This phase I trial studies the side effects of adding anakinra and tocilizumab to standard treatment with nivolumab and ipilimumab and to see how well it works in treating melanoma patients who are 50 years of age or older.
- Trial name
- NCT07838974
- Testing
- Anakinra, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California